Published in J Rehabil Med on July 01, 2008
Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology (2012) 2.50
Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res (2011) 1.97
Uncovering treatment burden as a key concept for stroke care: a systematic review of qualitative research. PLoS Med (2013) 1.79
Randomized controlled trial of surface peroneal nerve stimulation for motor relearning in lower limb hemiparesis. Arch Phys Med Rehabil (2013) 0.90
Changes in female support network systems and adaptation after breast cancer diagnosis: differences between older and younger patients. Gerontologist (2009) 0.85
The relationship between employment and social participation among Australians with a disabling chronic health condition: a cross-sectional analysis. BMJ Open (2013) 0.85
Cerebral microbleeds and quality of life in acute ischemic stroke. Neurol Sci (2011) 0.85
Embracing change: practical and theoretical considerations for successful implementation of technology assisting upper limb training in stroke. J Neuroeng Rehabil (2012) 0.83
The effects of a rhythm and music-based therapy program and therapeutic riding in late recovery phase following stroke: a study protocol for a three-armed randomized controlled trial. BMC Neurol (2012) 0.79
Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives. Tremor Other Hyperkinet Mov (N Y) (2014) 0.79
Environmental barriers experienced by stroke patients in Musanze district in Rwanda: a descriptive qualitative study. Afr Health Sci (2011) 0.77
Development and validation of participation and positive psychologic function measures for stroke survivors. Arch Phys Med Rehabil (2010) 0.76
Association of quality of life of carers with quality of life and functional independence of stroke survivors. J Family Med Prim Care (2016) 0.75
Life after Stroke in an Urban Minority Population: A Photovoice Project. Int J Environ Res Public Health (2017) 0.75
Influence of Sociodemographic and Stroke-related Factors on Availability of Social Support among Nigerian Stroke Survivors. Ann Med Health Sci Res (2015) 0.75
Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 19.43
Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA (1995) 11.68
Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet (2004) 7.33
Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA (2006) 3.50
Choosing measures of health status for individuals in general populations. Am J Public Health (1981) 2.60
Validation of the Short Form 36 (SF-36) health survey questionnaire among stroke patients. Stroke (1996) 2.28
Quality of life after stroke. Stroke (1996) 2.11
Are the ICF Activity and Participation dimensions distinct? J Rehabil Med (2003) 2.04
Standards for validating health measures: definition and content. J Chronic Dis (1987) 2.03
Agreement between patient and proxy assessments of health-related quality of life after stroke using the EQ-5D and Health Utilities Index. Stroke (2004) 1.66
The significance of quality of life in health care. Qual Life Res (2003) 1.47
Health-related quality of life among long-term survivors of stroke : results from the Auckland Stroke Study, 1991-1992. Stroke (2000) 1.45
Depression after stroke: a prospective epidemiological study. J Am Geriatr Soc (2004) 1.40
Measuring social participation: reliability of the LIFE-H in older adults with disabilities. Disabil Rehabil (2004) 1.31
Activities, participation and satisfaction one-year post stroke. Disabil Rehabil (2007) 1.30
Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age. Stroke (2002) 1.25
Depression or apathy and functional recovery after stroke. Int J Geriatr Psychiatry (2007) 1.10
Assessment of participation outcomes in randomized controlled trials of stroke rehabilitation interventions. Int J Rehabil Res (2007) 1.07
Assessment of clinical outcomes in acute stroke trials. Stroke (1998) 1.05
Is social participation associated with quality of life of older adults with physical disabilities? Disabil Rehabil (2004) 1.03
Depressive symptoms and independence in BADL and IADL. J Rehabil Res Dev (2007) 1.02
Outcome measures for clinical rehabilitation trials: impairment, function, quality of life, or value? Am J Phys Med Rehabil (2003) 0.95
Interdependence of stroke survivors' recovery and their relatives' attitudes and health: a contribution to investigating the causal effects. Disabil Rehabil (2007) 0.90
Short-term changes in and predictors of participation of older adults after stroke following acute care or rehabilitation. Neurorehabil Neural Repair (2007) 0.88
Measuring health outcomes in stroke survivors. Arch Phys Med Rehabil (2002) 0.87
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care (2007) 12.71
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol (2014) 6.64
Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol (2007) 6.24
Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med (2002) 5.69
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes (2003) 5.58
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol (2011) 5.43
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger. Assessment (2011) 4.21
Representativeness of the Patient-Reported Outcomes Measurement Information System Internet panel. J Clin Epidemiol (2010) 4.18
Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol (2002) 4.16
Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res (2009) 4.13
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (2004) 3.85
Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health (2008) 3.68
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes (2007) 3.66
Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol (2012) 3.65
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol (2004) 3.57
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol (2013) 3.48
A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof (2005) 3.43
Assessment of neurological and behavioural function: the NIH Toolbox. Lancet Neurol (2010) 3.20
Item response theory analyses of physical functioning items in the medical outcomes study. Med Care (2007) 3.10
Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol (2005) 2.98
Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol (2007) 2.97
Development of a PROMIS item bank to measure pain interference. Pain (2010) 2.85
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.82
Efficiency of static and computer adaptive short forms compared to full-length measures of depressive symptoms. Qual Life Res (2009) 2.55
General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof (2005) 2.51
Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes (2006) 2.48
Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain (2007) 2.47
Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group. J Clin Oncol (2003) 2.41
Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. J Rheumatol (2009) 2.39
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol (2008) 2.34
Item banking to improve, shorten and computerize self-reported fatigue: an illustration of steps to create a core item bank from the FACIT-Fatigue Scale. Qual Life Res (2003) 2.32
Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol (2005) 2.27
Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol (2011) 2.24
Evaluating equivalency between response systems: application of the Rasch model to a 3-level and 5-level EQ-5D. Med Care (2007) 2.22
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst (2002) 2.19
Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol (2010) 2.19
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer (2002) 2.17
A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol (2004) 2.14
Predicting EuroQol (EQ-5D) scores from the patient-reported outcomes measurement information system (PROMIS) global items and domain item banks in a United States sample. Qual Life Res (2009) 2.10
Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.08
Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res (2011) 1.97
ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res (2013) 1.96
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol (2004) 1.95
Symptoms and treatment burden associated with cancer treatment: results from a cross-sectional national survey in the U.S. Support Care Cancer (2008) 1.89
Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 1.88
Issues in the development of an item bank. Arch Phys Med Rehabil (2003) 1.87
The use of PROMIS and assessment center to deliver patient-reported outcome measures in clinical research. J Appl Meas (2010) 1.87
Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care (2007) 1.87
Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa. J Am Geriatr Soc (2007) 1.79
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol (2007) 1.77
Cognition assessment using the NIH Toolbox. Neurology (2013) 1.73
The neurology quality-of-life measurement initiative. Arch Phys Med Rehabil (2011) 1.71
Factor analysis techniques for assessing sufficient unidimensionality of cancer related fatigue. Qual Life Res (2006) 1.70
Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr (2005) 1.70
Late effects of cancer and hematopoietic stem-cell transplantation on spouses or partners compared with survivors and survivor-matched controls. J Clin Oncol (2007) 1.70
Using focus groups to inform the Neuro-QOL measurement tool: exploring patient-centered, health-related quality of life concepts across neurological conditions. J Neurosci Nurs (2007) 1.70
Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol (2005) 1.69
Intracerebral hemorrhage and delirium symptoms. Length of stay, function, and quality of life in a 114-patient cohort. Am J Respir Crit Care Med (2013) 1.68
Content validity of patient-reported outcome measures: perspectives from a PROMIS meeting. Qual Life Res (2011) 1.68
An item response theory-based pain item bank can enhance measurement precision. J Pain Symptom Manage (2005) 1.68
The talking touchscreen: a new approach to outcomes assessment in low literacy. Psychooncology (2004) 1.67
Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res (Hoboken) (2011) 1.67
Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology (2002) 1.64
How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. Arch Phys Med Rehabil (2011) 1.64
Measuring stigma across neurological conditions: the development of the stigma scale for chronic illness (SSCI). Qual Life Res (2009) 1.63
Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage (2007) 1.62
I. NIH Toolbox Cognition Battery (CB): introduction and pediatric data. Monogr Soc Res Child Dev (2013) 1.61
What does participation mean? An insider perspective from people with disabilities. Disabil Rehabil (2008) 1.61
Measuring quality of life in patients with melanoma: development of the FACT-melanoma subscale. J Support Oncol (2005) 1.58
Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med (2011) 1.57
Analysis of differential item functioning in the depression item bank from the Patient Reported Outcome Measurement Information System (PROMIS): An item response theory approach. Psychol Sci Q (2009) 1.56
Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw (2008) 1.55
NIH toolbox for assessment of neurological and behavioral function. Neurology (2013) 1.52
Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc (2010) 1.51
Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol (2012) 1.51
Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol (2003) 1.49
Patient-reported outcomes measurement information system (PROMIS) domain names and definitions revisions: further evaluation of content validity in IRT-derived item banks. Qual Life Res (2010) 1.48
Real-time clinical application of quality-of-life assessment in advanced lung cancer. Clin Lung Cancer (2002) 1.47
Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil (2002) 1.47
The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer (2006) 1.47
The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. Clin Trials (2014) 1.46
Health outcomes assessment in vulnerable populations: measurement challenges and recommendations. Arch Phys Med Rehabil (2003) 1.44